Influence of Sokatin® on parameters of the mental and psychic function

ISRCTN ISRCTN27842378
DOI https://doi.org/10.1186/ISRCTN27842378
Secondary identifying numbers 750402.01.026
Submission date
08/06/2010
Registration date
19/07/2010
Last edited
19/07/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Signs and Symptoms
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Andreas Hahn
Scientific

Am Kleinen Felde 30
Hannover
30167
Germany

Study information

Study designSingle centre open explorative study
Primary study designInterventional
Secondary study designCohort study
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use contact details below to request a patient information sheet
Scientific titleInfluence of Sokatin® on parameters of the mental and psychic function: An open label, explorative study
Study objectivesThe objective of the study is to assess the influence of Sokatin on the mental and psychic efficiency in volunteers with mild symptoms of exhaustion or fatigue
Ethics approval(s)Freiburg Ethics Committee (Freiburger Ethik-Kommission) approved on the 10th of May 2010 (ref: 010/1763)
Health condition(s) or problem(s) studiedCondition: mild symptoms of exhaustion or fatigue
InterventionOne tablet of 500 mg Sokatin® per day in the morning for eight weeks.
The intake phase will be eight weeks.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase II
Drug / device / biological / vaccine name(s)Sokatin®
Primary outcome measure1. Numerical Analogue Scales: motivation, concentration, exhaustion, resilience and somatic symptoms, measured at baseline, day 7 and weeks 4 and 8
2. Multidimensional Fatigue Inventory 20, measured at baseline, day 7 and weeks 4 and 8
3. Global Self-rating of Efficacy, measured at baseline, day 7 and weeks 4 and 8
4. SF-36 Health Survey, assessed at weeks 4 and 8
5. Sheehan Disability Scale, measured at baseline, day 7 and weeks 4 and 8
6. Fatigue Impact Scale, assessed at weeks 4 and 8
Secondary outcome measuresNone
Overall study start date15/06/2010
Completion date31/12/2010

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants50
Key inclusion criteria1. Male and female caucasians aged 30 to 60 years
2. Written informed consent
3. Readiness, and ability on the part of the subject to comply with the physician’s instructions
4. At least 3 of the symptoms listed below assessed as > 5 on NASs:
4.1. motivation
4.2. concentration
4.3. exhaustion
4.4. resilience
4.5. somatic symptoms
Key exclusion criteria1. Concomitant medications:
1.1. Antidepressives
1.2. Supplements with ingredients of the test substance
1.3. Corticosteroids
1.4. Immunosuppressive agents
1.5. Non-steroidal anti-inflammatory agents (NSAIDs) within one month before study start
1.6. Antibiotics within one month before study start
1.7. Vitamin and mineral nutrients supplement in dosages considerable above the recommended daily allowance
1.8. Laxatives (regular)
2. Diagnosed disease considered as cause of exhaustion or fatigue:
2.1. Chronic infectious diseases
2.2 Immune mediated diseases
2.3. Myasthenia
2.4. Neurological diseases
2.5. Cardio respiratory diseases
2.6. Metabolic diseases
2.7. Psychiatric diseases
2.8. Severe sleep disorder
3. Other diseases:
3.1.Severe chronic diseases
3.2. Apparent cardio vascular disease
3.3. Renal insufficiency
3.4. Liver diseases
3.5. Chronic disorders of the gastro-intestinal tract
3.6. Heart surgery
3.7. Surgery on digestive tract
3.8. Planned surgery
4. Pregnancy and lactation
5. Alcohol and/or substance abuse or dependence
6. Participation in another experimental trial at the same time or within the past 30 days before enrolment
7. Known hypersensitivity to ingredients of the test substance
Date of first enrolment15/06/2010
Date of final enrolment31/12/2010

Locations

Countries of recruitment

  • Germany

Study participating centre

Am Kleinen Felde 30
Hannover
30167
Germany

Sponsor information

Dr. Willmar Schwabe GmbH & Co. KG (Germany)
Industry

Willmar-Schwabe-Straße 4
Karlsruhe
76227
Germany

ROR logo "ROR" https://ror.org/043rrkc78

Funders

Funder type

Industry

Dr. Willmar Schwabe GmbH & Co. KG (Germany)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan